WuXi Biologics will be attending
J.P. Morgan 2020 & Biotech Showcase

Click Here to Schedule a Meeting
WuXi Vaccines to Build a $240 Million Manufacturing Facility in Ireland
WuXi Biologic' subsidiary WuXi Vaccines, engaged in human vaccine Contract Development & Manufacturing Organization (CDMO) business, will invest $240 million to build a new vaccine manufacturing facility in Ireland. This investment follows the 20-year manufacturing Letter of Intent signed by WuXi Vaccines earlier this year.
Biologic Products DNA to IND Timeline in 9 Months - Yes It Can Be Done!

WuXi Biologics Congratulates Tychan for Dosing First Patient of a Zika Antibody after Record 9 Months of Development

WuXi Biologics Congratulates Tychan on First-in-Class Monoclonal Antibody for Yellow Fever after Record 7 Months of Development
Read More 
Antibody Drug Conjugate (ADC) Development and Manufacturing Challenges & Solutions

WuXi Biologics to Expand Integrated Biologics Conjugation Solution Center to Include Commercial Manufacturing
New Flexible Bispecific Antibody Format Demonstrates Improved Therapeutic Properties and Manufacturability

WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel Bispecific Antibody Immunotherapeutics

I-Mab Biopharma Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Three Bispecific Antibody Programs
Read More 
Is Continuous Biomanufacturing a Good Fit for Your Process?

WuXi Biologics Achieves Breakthrough Titer of 51g/L in Cell Culture Productivity
December 9-13, 2019
WuXi Biologics wins 2019 CMO Leadership Awards in all six core categories

WuXi Biologics receive's "Asia's Best CMO of 2018" award from IMAPAC